Merck 2Q FY26 net loss widens to $1.34 billion; sales rise 5% to $16.61 billion

• Merck posted a GAAP net loss attributable to shareholders of USD 1.34 billion, or USD 0.54 per share, in 2Q26.
• Net sales rose 5% to USD 16.61 billion from a year earlier, while GAAP other income swung to USD 99 million from an expense.
• GAAP loss before taxes widened to USD 683 million from profit, as cost of sales climbed 24% to USD 4.4 billion.
• On a non-GAAP basis, net loss narrowed to USD 330 million, or USD 0.13 per share, from GAAP results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.